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Neuropeptides are critical signaling molecules, involved in the regulation of diverse
physiological processes including energy metabolism, pain perception and brain cognitive
state. Prolonged general anesthesia has an impact on many of these processes, but the
regulation of peptides by general anesthetics is poorly understood. In this study, we present
an in-depth characterization of the hypothalamic neuropeptides of the tree shrew during
volatile isoflurane/nitrous oxide anesthesia administered accompanying a neurosurgical
procedure. Using a predicted-peptide database and hybrid spectral analysis, we first
identified 85 peptides from the tree shrew hypothalamus. Differential analysis was then
performed between control and experimental group animals. The levels of 12 hypothalamic
peptideswereup-regulated followingprolonged general anesthesia. Our study revealed for the
first time that several neuropeptides, including alpha-neoendorphin and somatostatin-14,
were altered during general anesthesia. Our study broadens the scope for the involvement of
neuropeptides in volatile anesthesia regulation, opening the possibility for investigating the
associated regulatory mechanisms.
1. Introduction
General anesthesia is characterized by several components
such as hypnosis and analgesia [1], and is used duringmedical
and experimental surgical procedures to reduce pain. An
extensive literature suggests that both injection and inhalation
general anesthetics exert their effects by acting on small
molecule neurotransmitter and neuromodulators in the brain
[2]. By binding to receptor proteins, general anesthetics can alter
neuronal activity, change the basal extracellular levels of
neurotransmitters, and generate various downstream effects.
Among these downstream effects are changes in neuropeptide
expression levels,whichmay importantly contribute tohypnotic
and analgesic effects of general anesthetics [3].
Neuropeptides act as neuromodulators, tuning the efficacy
of fast acting neurotransmitters, and are thought to be mostly
released by volume transmission. A line of evidence has
demonstrated that general anesthesia can evoke the extracel-
lular release of neuropeptides and/or increasing the expression
of neuropeptides intracellularly [4,5]. Opioidneuropeptideshave
been a major focus of investigation, with a number of studies
showing that inhalation anesthetics, such as nitrous oxide or
isoflurane, up-regulate the expression of a number of opiate
neuropeptides, such asmet-enkephalin and dynorphin [4,6–10].
These enhancements in opiate neuropeptides have been linked
to the maintenance and reinforcement of certain aspects of
general anesthesia induced by volatile anesthetics. Other work
has examined the effects of exogenous neuropeptide applica-
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tion on anesthesia. For example, somatostatin has been shown
to induce general anesthesia. These studies enforce the
presumed functional links between neuropeptides and general
anesthesia. However, compared to well characterized influence
of general anesthesia on small molecule neurotransmitters [2],
we lack a comprehensive view on how general anesthesia alters
the expression of various endogenous neuropeptides in the
brain. Comprehensive characterization of the neuropeptidome
during anesthesia can thus be useful to understand the
involvement of neuropeptides to general anesthesia.
Neuropeptides are produced from protein precursors,
stored in neurons and released into the extracellular space
during activity of these neurons [12]. A single precursor can
give rise to many neuropeptides but with distinct anesthetic
properties [3]. Thus, selective and sensitive methods are
needed for monitoring various individual neuropeptides
with high accuracy and confidence. In the present study, we
aim to characterize the effects of nitrous oxide and isoflurane,
a combination of two commonly used inhalation anesthetics,
on the hypothalamic neuropeptidome. The hypothalamus is a
brain structure that is particularly rich in neuropeptides, and
has previously been implicated in anesthesia [3]. We conducted
our study in tree shrews (Tupaia belangeri), a non-rodent small
mammalian species that is a close relative of primates and is
considered to be a useful animalmodel for biomedical research
[13].
We first sought to give a comprehensive identification of
hypothalamic neuropeptidome of tree shrews. As no complete
genome or proteome of tree shrews was available for database
search, the identification of endogenous peptides in the tree
shrew hypothalamus presented a challenge. To overcome this
problem, we thus constructed a database of predicted peptides
by performing in silico cleavage of neuropeptide precursors
collected from species in Euarchontoglires clade (see Fig. 1A).
Using a predicted peptide database allows the search to be
redistricted to potential or known neuropeptides, avoiding the
identification of peptide signal or polypeptides from the protein
precursors. The construction of database for tree shrew peptide
identification is possible because neuropeptides are highly
conserved across species [14], and particularly for species
closely related to tree shrews in the Euarchonta clade. We
then identified endogenous peptides present in the tree shrew
hypothalamus based on a hybrid de novo sequencing-guided
MS/MS search engine coupled with our predicted-peptide
database. We proceeded to compare differences in peptide
expression levels between control tree shrews and the tree
shrews subjected to isoflurane-nitrous oxide anesthesia, which
was administered accompanying an experimental surgical
procedure. Our study allows an in-depth characterization of
the tree shrew hypothalamic peptidome, uncovering multiple
peptides involved in general anesthesia.
2. Material & methods
2.1. Chemicals
LC–MS grade acetonitrile and formic acid were purchased
from Fisher Scientific (New Jersey, USA) and Fluka (Wisconsin,
USA), respectively. Pure waterwas prepared by GenPure system
(TKA,Niederelbert, Germany) Siliconizedmicro centrifuge tubes
(2 mL) were purchased from Eppendorf (Hamburg, Germany).
Internal standard peptide ([D-Ala2]-Leucine enkephalin was
purchased from Sigma Aldrich (Schnelldorf, Switzerland)
Microcon centrifugal filter devices (Vivacon 500)were purchased
from Sartorius AG (Goettingen, Germany Germany).
2.2. Animals
Tree shrew (T. belangeri) were used in the experiments. All
animals were housed under constant temperature and
humidity with free access to food and water. All procedures
with live animals were conducted in accordance with the
veterinary office of Fribourg, Switzerland. Three long-term
anesthetized animals initially received Ketanarkon (ketamine,
100 mg/kg, Streuli Pharma AG, Uznach, Switzerland) and
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Fig. 1 – Phylogenic aspect and database construction. (A.) The phylogenic tree of the Euarchontoglires superorder shows the
taxonomic proximity of tree shrews (Scandentia order) to the Primates and Glires orders. (B.) The predicted peptides database
is constructed by processing the neuropeptide precursors following the neuropeptide cleavage rules.
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Atropine (Sintetica SA, Mendrisio, Switzerland) (0.02 mg/kg).
The animals were artificially respirated at 100 strokes per
minute (Harvard Instruments Respirator, Holliston, MA, USA)
using amixture of 70%N2O and 30% oxycarbon (95%O2/5% CO2)
and isoflurane (Abbott Laboratories, Illinois, USA) (0.5%–1.5%)
for a period of about twelve hours. At the beginning of this
period, a small incision was made into the cranium and
electrodes were advanced into the visual cortex for the study
of electrophysiological responses to visual stimuli [15]. Three
control animals were briefly anesthetized using Ketanarkon
(ketamine, 100 mg/kg, Streuli Pharma AG, Uznach, Switzerland)
by s.c. injection. All animals were sacrificed by decapitation.
2.3. Sample preparation
The sample preparation is a crucial step in peptidomic
experiments. Enzyme inactivation should be performed imme-
diately post-sampling, otherwise protein degradation products
would contaminate the sample and the endogenous peptides
would be difficult or impossible to analyze. Following decapita-
tion, the headwas immediately heated up to 80 °C in 16 s using
microwave irradiation as described in Che et al. [16]. The brain
was removed and stored at −80 °C. Hypothalami were dissected
from the denaturized brain.
The tissue is homogenized and peptides were extracted
three times using a gradient of methanol solution. The first
solution was 10% methanol (Fisher Scientific, Hampton, NH)
with 0.2% formic acid, the second 30% methanol with 0.2%
formic acid and the final 50% methanol with 0.2% formic acid,
15 μl of total solvent was used per mg of tissue. Each time, the
sample was homogenized by Precellys 24 homogenizer (Bertin
Technologies, Montigny-le-Bretonneux, France) for 20 s twice.
Each sample suspension was then centrifuged at 22,000 g for
60 min at 4 °C to remove insoluble material. The combination
of all supernatants was transferred to a 10 kDa cut-off spin
column (Vivacon, Sartorius AG, Goettingen, Germany) after
washing and centrifuged for 90 min at 14,000 g at 4 °C to
exclude bigger peptides or small proteins.
2.4. Qualitative LC–MS analysis
The brain sample extracts were submitted to LC-Fourier
Transformation (FT)–MS/MS for peptide identification. In each
LC–FT-MS/MS analysis, 5 μl extract was loaded on a 2.4 cm
trap-column (100 μm inner diameter) for desalting. The trap
column was packed in house with Reprosil-Pur C18 5 μm resin
(Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). The
peptides were then separated by a 100-minute gradient on a
20 cm long Proxeon nanoESI emitter (75 μm inner diameter,
360 μm outer diameter) packed in house with Reprosil-Pur C18
3 μmresin (Dr.MaischGmbH,Ammerbuch-Entringen,Germany).
The gradient started from 2 to 20% B during the first 12 min,
increased to 50% B in the next 68 min, thenwas kept at 95% B for
20 min. Mobile phase A was 0.2% (v/v) formic acid in water.
Mobile phase B was 5% (v/v) water and 0.2% (v/v) formic acid in
acetonitrile (Sigma-Aldrich Co, St Louis, MO). The flow rate was
300 nl/min. The LC–MS analysis was performed on a hybrid
linear ion trap and Orbitrap mass spectrometer (LTQ Discovery
Orbitrap, Thermo Fisher, San Jose, CA, USA). The spray voltage
was 1.5 kV, The capillary temperature of electrospray ionization
(ESI) source was 200 °C.Peptides were fragmented using a
collision energy of 35 units and an activation time of 30 ms. LC–
FT-MS/MS analysis was conducted using data-dependent acqui-
sition in which the mass spectrometer automatically switches
between a high resolution survey scan followed by consecutive
CID fragmentation of the 5 most abundant multiply charged
peptides eluting at this moment from the nano-LC column.
2.5. Peptide identification & database
Thedatabasewas constructed by first downloading a list of 2405
protein precursors [17,18] from the Uniprot database (http://
www.uniprot.org/, 7 July 2010) restricted to Euarchontoglires
species. All these sequences were then submitted to an in silico
peptide cleavage using custom made software written in Perl,
according to the following template: (K/R)Xm(K/R) Xk (K/R)Xn(K/R)
where X is any amino acid,m and n correspond to 0, 2, 4, 6, and k
corresponds to 3–50. The residues Xk represent the predicted
neuropeptide sequence. The predicted-peptide-database com-
prises the resulting sequences (50,377 entries).
Acquired MS/MS data were submitted to de novo sequencing
using Peaks Studio software (v5.3, Bioinformatics Solutions, Inc.,
Waterloo, ON, Canada), with these parameters: enzyme (none),
variablemodifications (Amidation −0.98 Da, acetylation of lysine
+42.01 Da, Pyro-glutamination fromglutamic acid −18.01 Da and
glutamine −17.03 Da),mass values (monoisotopic); peptidemass
tolerance (10 ppm), fragment mass tolerance (0.05 Da). Database
interrogation was done with Peaks Protein ID using the same
parameters as de novo sequencing and the custom-made
predicted-peptide-database. Only peptideswith a false discovery
rate of less than 1% were considered. For the SPIDER similarity
search, these additional settings were specified: homology
match, fragment ion tolerance 0.05 Da, and Leucine equal to
isoleucine.
Endogenous peptide fragmentation MS/MS spectra are
more difficult to interpret than tryptic peptides, so all relevant
hits were verified according to the following rules: The
majority of the most intense MS/MS ions should belong either
to the y and b products of the precursor peptide or have a
relevant link to these products, e.g., loss of H2O from an ion
containing a serine residue; if present, the y ion originating
from the fragmentation at the proline residue and the
corresponding b ion should have increased intensity and at
least three consecutive amino acids in the de novo sequencing
has to be present [19].
2.6. Peptide quantification
Peptide differential analysis was conducted using the left
hypothalami of six tree shrews (3 controls, 3 long-term
anesthetized animals). The LC–FT-MS analysis of each hypo-
thalamus sample was repeated 2 times for measuring the
intensities of peptide precursors. Label-free peptide profiling
was performed using SIEVE 1.3 (Service package 2, Thermo
Scientific, San Jose, CA). SIEVE is a label-free differential
analysis software that aligns and determines features across
samples prepared from different conditions [20]. The following
parameters were used in the peak alignment and frame
generation: m/z min=300, m/z max=1500, frame time width=
6.0 min, frame m/z width=0.02 Da, retention time start=
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Table 1 – Peptides identified in tree shrew hypothalamus. PTMS: Delta mass −17.03 Da, Pyro-Glu; Delta mass −0.98 Da, amidation; Delta mass −42.01 Da, acetylation.
* reflected the sequence identified by homology search. The number under the bracket [X-X] indicates the fragmentation position of a neuropeptide.
Precursor Uniprot
accession
number
Peptide name Sequence −10lgP or
Spider
score
M/Z Z Mr (Da) Mass
error
(ppm)
Carboxypeptidase E P16870 WE-14 [1–11] Q(−17.03)EPGAPAAGM 35.7 456.200 2 910.400 0.8
Chromogranin-A P10645 WSKMDQLAKEL 41.45 450.235 3 1347.707 −0.2
Cocaine- and
amphetamine-regulated
transcript protein
P56388 CART(55–102) IPIYEKKYGQVPM 37.02 522.618 3 1564.854 0.1
Cocaine- and
amphetamine-regulated
transcript protein
P56388 CART(1–52) [1–9] Q(−17.03)EDAELQPR 47.4 534.750 2 1067.501 −0.9
Delta preprotachykinin I Q9Z0K2 DAGHGQISHKMGYE 62.01 510.564 3 1528.694 −0.2
Delta preprotachykinin I Q9Z0K2 DAGHGQISHKMGYERSAMQNYE 74.03 837.038 3 2508.114 0.4
FMRFamide-related peptides Q9WVA8 Neuropeptide SF SPAFLFQPQRF(− .98) 44.19 668.860 2 1335.721 −1.1
Gamma preprotachykinin Q9Y494 Q(−17.03)IKEELPEPFEHLLQRIA 60.5 725.058 3 2172.177 −1.3
Gamma preprotachykinin I Q9Z0K1 ALNSVGYE 36.95 852.410 1 851.410 1.4
Gamma preprotachykinin I Q9Z0K1 ALNSVGYERSAMQNYE 67.64 916.418 2 1830.836 0.9
Glucagon P55095 Glucagon-like peptide 1(7–36) HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR(− .98) 84.05 824.923 4 3295.692 0.4
Neuroendocrine convertase 1 P29120 SLDDDRVIWAEQQYQKERS 46.5 789.391 3 2365.175 10.2
Neuropeptide Y P68006 Neuropeptide Y YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY(− .98) 65.17 854.824 5 4269.121 0.8
Neurosecretory protein VGF O15240 Neurosecretory protein VGF [562–593] RAQEEAEAEERRLQEQEELENYIEHVLLRRP 73.33 773.394 5 3861.972 0.8
Neurosecretory protein VGF O15240 Neurosecretory protein VGF [573–593] RLQEQEELENYIEHVLLRRP 62.68 641.844 4 2563.378 −0.3
Neurotensin/neuromedin N Q9D3P9 Neurotensin Q(−17.03)LYENKPRRPYIL 42.6 558.309 3 1671.927 −2.6
Neurotensin/neuromedin N Q9D3P9 Neurotensin QLYENKPRRPYIL 41.09 423.241 4 1688.965 0.1
Orexin O55241 Orexin-B [1–12] RPGPPGLQGRLQ 36.3 425.914 3 1274.742 −0.1
Pituitary adenylate
cyclase-activating polypeptide
P18509 PACAP 27 [16–27] Q(−17.03)MAVKKYLAAVL(− .98) 47.79 658.891 2 1315.783 0
Probable ATP-dependent RNA
helicase DDX41
Q9UJV9 VRKLDEFLETGDLRTM* 15.5 641.671 3 1922.0154 0.3
Proenkephalin-A P01210 PENK(143–183) [2–18] A(+42.01)EEDDSLANSSDLLKEL 53.75 945.949 2 1889.898 5.2
Proenkephalin-A P01210 Met-enkephalin-Arg-Phe [2–7] GGFMRF 43.31 357.673 2 713.347 2
Proenkephalin-A P01210 Peptide E VGRPEWWMDYQKRYGGFL 52.93 572.781 4 2287.125 −1.5
Proenkephalin-A P01210 Peptide E (Frag) PEWWMDYQ 54.5 577.734 2 1153.469 0.8
Proenkephalin-A P01210 Peptide E (Frag) RPEWWMDYQ 52.91 655.784 2 1309.569 0.3
Proenkephalin-A P01210 Peptide E (Frag) VGRPEWW(+15.99)MDYQ 27.65 741.825 2 1481.651 −1.7
Proenkephalin-A P01210 Peptide E (Frag) VGRPEWWM 42.93 530.754 2 1059.509 −0.9
Proenkephalin-A P01210 Peptide E (Frag) VGRPEWWMDY 66.81 669.799 2 1337.599 −1.2
Proenkephalin-A P01210 Peptide E (Frag) VGRPEWWMDYQ 59.77 733.829 2 1465.659 0.1
Proenkephalin-A P01210 Leu-enkephalin YGGFL 33.61 556.276 1 555.276 −0.2
Proenkephalin-A P01210 Met-enkephalin YGGFM 35.12 574.234 1 573.234 1.9
Proenkephalin-A P01210 Met-enkephalin-Arg-Gly-Leu YGGFM(+15.99)RGL 49.63 458.720 2 915.441 0
Proenkephalin-A P01210 Met-enkephalin-Arg-Gly-Leu YGGFMRGL 52.46 450.724 2 899.448 1.8
Proenkephalin-A P01210 Met-enkephalin-Arg-Gly-Leu [2–8] GGFMRGL 44.17 369.192 2 736.384 1.2
Proenkephalin-A P01210 Met-enkephalin-Arg-Phe YGGFM(+15.99)RF 51.69 447.202 2 892.405 0.7
Proenkephalin-A P01210 Met-enkephalin-Arg-Phe YGGFMRF 49.82 439.204 2 876.409 −0.6
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Proenkephalin A P01210 Metorphamide YGGFMRRV( .98) 38.16 492.763 2 983.527 0.6
Proenkephalin-A P01210 SPQLDDEAKEL* 28 622.805 2 1243.611 3
Proenkephalin-A P01210 SPQLDDEAKELQ* 31.5 686.833 2 1371.666 0.1
Proenkephalin-B P06300 Dynorphin A [10–17] PKLKWDNQ 47.07 514.779 2 1027.558 −0.7
Proenkephalin-B P06300 Alpha-neoendorphin YGGFLRKYPK 46.93 614.845 2 1227.691 0.2
Progonadoliberin-1 P01148 Gonadoliberin-1 Q(−17.03)HWSYGLRPG(− .98) 60.14 591.792 2 1181.585 −1.7
Pro-MCH P20382 Neuropeptide-glutamic acid-isoleucine EIGDEENSAKFPI(− .98) 53.58 724.356 2 1446.713 −0.3
Pro-melanin concentrating hormone B5LWR2 HGLPLNLAIKPYLALKGSVA 59.58 692.417 3 2074.251 −0.4
Pro-opiomelanocortin P01189 Lipotropin gamma DEGPYRMEHFRWGSPPKD 61.57 735.337 3 2203.011 −0.2
Pro-opiomelanocortin P01189 Melanotropin alpha SYSMEHFRWGKPV(− .98) 51.71 541.602 3 1621.806 1.1
Pro-opiomelanocortin P01194 Beta-endorphin [1–27] YGGFMTSEKSQTPLVTLFKNAIIKNVH 60.56 756.650 4 3022.6 −8
Pro-opiomelanocortin P01194 Beta-endorphin YGGFMTSEKSQTPLVTLFKNAIIKNVHKKGQ 53.85 578.314 6 3463.887 −6.1
ProSAAS Q9UHG2 ALAHLLEAE 41.22 483.766 2 965.533 0.8
ProSAAS Q9UHG2 ALAHLLEAERQE 46.08 460.581 3 1378.745 2.6
ProSAAS Q9QXU9 AVPRGEAAGAVQEL 53.16 684.367 2 1366.734 −0.3
ProSAAS Q9QXU9 AVPRGEAAGAVQELARALAHLLEAERQ 70.84 707.388 4 2825.554 −0.3
ProSAAS Q9QXU9 AVPRGEAAGAVQELARALAHLLEAERQE 85.89 985.863 3 2954.589 −0.3
ProSAAS Q9QXU9 GEAAGAVQELARALAHLLEAERQE 71.36 844.776 3 2531.330 −0.3
ProSAAS Q9UHG2 PPEGVLGALLRV 58.88 610.871 2 1219.743 0.1
ProSAAS Q9UHG2 VLGALLRV 34.57 420.787 2 839.574 0.2
ProSAAS Q9QXU9 PEN VMGQDLSECMPPEGVLGALLRV* 29.2 772.061 3 2313.183 3.5
Protachykinin-1 P41540 AFLAPVASQLF* 14.8 582.328 2 1162.656 3.1
Protachykinin-1 P20366 Neuropeptide K [1–23] DADSSIEKQVALLKALYGHGQIS 67.07 815.100 3 2442.302 2.1
Protachykinin-1 P20366 Neuropeptide K [1–24] DADSSIEKQVALLKALYGHGQISH 85.53 645.840 4 2579.363 0.2
Protachykinin-1 P20366 Substance P KPQQFFGLM(− .98) 50.86 547.794 2 1093.588 0.1
Prothyroliberin P20396 EEEYGVDEEEEEEAGECHEHC* 22.14 1240.997 2 2479.994 0
Rho GTPase-activating protein 22 Q8BL80 PLQWKSSFRE* 16 426.560 3 1276.682 3
Secretogranin I P16014 DGVAELDQLLHY 54.9 686.841 2 1371.682 0.4
Secretogranin I P16014 DQLLHY 37.72 788.393 1 787.393 0.2
Secretogranin I P16014 GVAELDQLLHY 56.22 629.328 2 1256.657 2.2
Secretogranin I P16014 Q(−17.03)YDGVAELDQL 52.58 617.285 2 1232.571 1
Secretogranin I P16014 Q(−17.03)YDGVAELDQLLH 60.96 742.356 2 1482.712 −0.5
Secretogranin I P16014 Q(−17.03)YDGVAELDQLLHY(− .98) 15.19 823.399 2 1644.798 3.1
Secretogranin I P16014 QYDGVAELDQLLHY 56.58 832.402 2 1662.804 0.5
Secretogranin I P16014 YDGVAELDQLLHY 62.46 768.371 2 1534.743 −1.2
Secretogranin II P13521 Secretoneurin [7–24] EQYTPQSLATLESVFQEL 61.03 1042.015 2 2082.030 0.1
Secretogranin II P13521 Secretoneurin [4–24] IVEEQYTPQSLATLESVFQEL 53.9 808.744 3 2423.232 −0.2
Secretogranin II P13521 Secretoneurin [13–24] SLATLESVFQEL 36.73 668.852 2 1335.705 −1
Secretogranin II P13521 Secretoneurin [10–24] TPQSLATLESVFQEL 60.64 831.931 2 1661.863 −1.2
Secretogranin II P13521 MQFPLMYEENSRDNPF* 49.5 1009.440 2 2016.880 −2.5
Secretogranin III P47868 ELSAERPLNEQIAE 48.75 799.905 2 1597.81 0.5
Secretogranin III P47868 ELSAERPLNEQIAEAE 52.61 899.941 2 1797.882 −3.5
Secretogranin III P47868 ELSAERPLNEQIAEAEAD 61.12 992.976 2 1983.953 0.1
Secretogranin V P05408 SVNPYLQGQRLDNVV 57.03 851.449 2 1700.899 0.3
Secretogranin V P05408 SVNPYLQGQRLDNVVA 60.69 886.968 2 1771.936 0
SH2B adapter protein 1 Q91ZM2 LNARAKPLDL* 14 555.834 2 1109.669 −0.5
Somatostatin P60041 Somatostatin-14 [1–12] AGCKNFFWKTFT 52.78 725.354 2 1448.709 2.4
Somatostatin P60041 Somatostatin-14 AGCKNFFWKTFTSC 67.75 820.374 2 1638.748 1
Somatostatin P60041 Somatostatin-28 [1–12] SANSNPAMAPRE 56.84 622.787 2 1243.575 −0.2
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15 min, retention time stop=85 min, peak intensity threshold=
10,000. Other parameters were set to the default values if they
were not mentioned. The differential analysis of identified tree
shrew peptides was conducted by loading their m/z and
retention time into Sieve as a seed file. The peptides with S/N
ratio higher than 10 and CV below 50% were accepted for
quantitative analysis. Twonormalizationmethodswere used in
the label-free quantitation. Total ion current (TIC) normaliza-
tion method was first used in the quantitative analysis. The
peak intensities of peptides were then normalized to a spiked
internal standard peptide [D-Ala2]-Leucine enkephalin (Spike
normalization). A t-test was used for significance analysis
(two-tailed distribution). The significance of the change was
accepted for a peptide if a frame had a p-value of less than 0.05
in both normalization methods. The reported p-values and
ratios of peptides given in the text represent the results
processed using Spike normalization (see Supplementary Fig. S1
for the results regarding TIC normalization).
3. Results
Our study, with the purpose to identify and quantify endoge-
nous hypothalamic peptides in the tree shrew hypothalamus,
was conducted in three steps: i) custom-made predicted-
peptide-database; ii) high accuracy LC–MS/MS data acquisition,
and subsequent hybrid data interpretation by using de novo
sequencing-guided search engine search or homology search;
and iii) label-free quantification for investigating the influence
of general anesthesia on the expression of hypothalamic
peptides.
To construct the database, we first collected the sequences
of known neuropeptide precursors from related species in
the Euarchontoglires clade (see Fig. 1A), based on the list of
reported neuropeptides, precursors and additional candidate
[17,18] (see Supplementary Table 1). Current studies showed
that neuropeptides are produced from their precursors by
different neuropeptide-processing enzymes in different path-
ways. Twomain pathways, cysteine and subtilisin-like protease
pathways, are known to be involved in cleavage mainly on
dibasic sites, which can be separated by 0, 2, 4 or 6 amino acids
[21,22]. The protein is submitted to in silico cleavage according to
the following template: (K/R)Xm(K/R)Xk(K/R)Xn(K/R), where X is
any amino acid, m and n correspond to 0, 2, 4, 6, and k
corresponds to 3–50. The residues Xk represent the predicted
neuropeptide sequence [23,24] (See the workflow presented in
Fig. 1B). This predicted-peptide database, restricted to known
or potential neuropeptide precursors of the Euarchontoglires
clade, is available on our website (http://www.unifr.ch/inph/
vclab/home/internal/neuropep_euarglire).
Using de novo sequencing-guided peptide search software
[25] on our database, we identified 75 peptides, which have
a sequence strictly identical to one or more sequences in
other species, with high confidence (FDR≤1%) (Table 1 and
Supplementary Fig. 2). Fig. 2A represents the interpretation of
the high accuracy MS/MS fragmentation spectrum at the
precursor ions at m/z 820.37 ([M+2H]2+). The search against
our database assigned this sequence to somatostatin-14,
corresponding to the amino acid string AGCKNFFWKTFTSC.
The presence of this peptide in the database results from the
cleavage of somatostatin precursor from four different species:
Homo sapiens (Uniprot P61278), Macaca fascicularis (Uniprot
P61279), Mus musculus (Uniprot P60041) and Rattus norvegicus
(Uniprot P600429), underlining the highly conserved nature of
somatostatin-14.
When de novo sequencing-guidedpeptide searchdidnot yield
a high confidence sequence for the MS/MS data, a homology
search [26,27] was conducted. This allowed us to identify a
tree shrew peptide based on its sequence similarity to one or
more peptides from other species in the database. Using this
approach, we were able to identify ten additional peptides
(homology search results in Table 1). Fig. 2B represents an
example of a peptide identified using homology search, with a
MS/MS fragmentation spectrum generated from the precursor
ion at m/z 426.56 ([M+3H]3+). De novo sequencing allowed us to
unambiguously attribute the sequence PL/IQWKSSFRE to the
MS/MS fragment spectrum, and subsequent homology search
assigned the sequence to a peptide derived from the precursor
Rho GTPase-activating protein 22. The alignment of other
known Euarchontoglires sequences suggests that this peptide
is not strictly identical between the different species. The major
difference occurs at the N-terminal of the peptide, as confirmed
by the presence of the fragment ions y9, y8, y7, b2 and b3. This tree
shrew peptide starts with Pro-Leu-Gln, whereas the correspond-
ing peptide in mouse (Glires order) starts with Pro-Val and the
peptide of human (Primate order) starts with Pro-Ser. Our
workflow allows the rapid identification of peptide sequences
with amino acid residue insertion, mutation or deletion, which
often occur between different species.
Having characterized the peptidome of the tree shrew
hypothalamus, we further examined how nitrous oxide-
isoflurane induced anesthesia influenced the expression
levels of hypothalamic peptides. We conducted a relative
quantitative analysis on animals that received anesthesia for
long term (12 h) compared to controls animals. For quantitative
analysis, a label-free quantification method was used to
investigate the different levels of peptides in the hypothalamus
in the presence or absence of anesthesia. We found that the
levels of 12 peptides increased significantly during anesthesia
(Fig. 3) using either TIC or Spike normalization data processing.
Among these peptides, six peptides, including alpha-
neoendorphin and dynorphin A [AA10-17], are derived from
proenkephalin A and B. One peptide was derived from the
somatostatin precursor, and two peptides belonged to the
protachykinin family. The other three significantly up-regulated
peptides were derived from cocaine- and amphetamine-
regulated transcript protein, SH2B adapter protein 1, and
neurotensin/neuromedin N. The normalized ratios of these
peptides comparing long-term anesthetized and control tree
shrews ranged from 1.5 to 7.5 according to the Spike method.
Somatostatin-14 showed a particularly large increase during
anesthesia (normalized ratio=7.46).
4. Discussion
The extent to which neuropeptides are modulated by and
contribute to general anesthesia is a topic of current research in
anesthesiology. Here we examined how peptide levels in the
hypothalamus aremodulated by general anesthesia induced by
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a combination of nitrous oxide and isoflurane in the tree shrew.
Since there was no preexisting peptide database available for
this species, we first constructed an appropriate database using
data from closely related mammalian species. Using this
database, we identified a total of 85 peptides in the tree shrew
hypothalamus, including 29neuropeptides.Of these, 12 peptides
were significantly up-regulated during long-term general anes-
thesia that was administered accompanying a neurosurgical
procedure.
Among the 12 up-regulated peptides, six were derived from
opiate peptide precursors. A line of evidence has demonstrated
that general anesthetics alter the levels of opioid peptides. For
example, ketamine administration increases Leu-enkephalin
release, while decreasing the release of Met-enkephalin [28].
Similarly, the application of isoflurane increases Leu-enkephalin
expression in the hypothalamus [4]. Nitrous oxide has been
strongly linked to neuropeptide release [3], with previous studies
highlighting that the application of nitrous oxide evokes
the release of several opiate peptides, such as enkephalins,
β-endorphin [29] and dynorphin A and B. The nitrous-oxide
inducedneuropeptide changes can be quite large. For example, a
cerebral spinal fluid (CSF) radioimmunoassay showed that
exposure to nitrous oxide leads to a 400-fold increase in
Met-enkephalin [30]. Consistent with this is a previous study
showing nitrous oxide induced elevations in tissue concentra-
tion of both Met-enkephalin and preproenkephalin hypotha-
lamic mRNA levels [31]. In our study we observed a trend
towards up-regulation of Met-enkephalin neuropeptide in the
hypothalamus, which however did not reach significance (p=
0.07). The elevation of Met-enkephalin in tree shrew hypothal-
amus was certainly less remarkable than that previously
observed in CSF [30]. This difference may be due to the
AGCKNFFWKTFTSC
AGCKNFFWKTFTSC
AGCKNFFWKTFTSC
Somastostin-14
[Tupaia belangeri]
[Homo sapiens]
[Mus Musculus]
PV WKSSFRQ
PLQWKSSFRE
Rho GTPase-activating protein 22 
[Tupaia belangeri]
[Homo sapiens]
[Mus Musculus] PS WKSSFRQ
A
B
Fig. 2 – Peptide identification (A.) The annotated MS/MS spectrum of the Somatostatin-14 peptide (AGCKNFFWKTFTSC, m/z
820.3743, [M+2H]2+) is presented. (B.) The alignment of the peptide sequence with the other Euarchontoglires Somatostatin-14
(Homo sapiens P61278,Mus musculus P60041) shows that they have an identical sequence. (C.) The annotated MS/MS spectrum
of the peptide from Rho GTPase-activating protein 22. (PL/IQWKSSFRE, m/z 426.5607, [M+3H]3+) is presented. (D.) The
alignment of the peptide sequence with the other Euarchontoglires sequences (Homo sapiens Q7Z5H3, Mus musculus Q8BL80)
shows different sequences.
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combinational use of nitrous oxide and isoflurane in our study
rather than the use of nitrous oxide alone, or could be due to
different media used for peptide measurement. In addition to a
trend for Met-enkephalin, we observed significant increases in
the levels of six other peptides derived from proenkephalin-A
and proenkephalin-B, including metorphamide and alpha-
neoendorphin. These peptides, some of which are members of
the classical opioid neuropeptide family, could play important
roles in potentiating analgesia by acting on opioid receptors.
Our study revealed that general anesthesia applied during
surgeric procedures leads to robust increases in the level
of somatostatin-14. Somatostatin-14, which regulates the
release of various neurotransmitters and other neuropeptides,
has diverse effects such as control of body temperature, blood
pressure and nociception [32]. Exogenously administrated
somatostatin-14 acts as a potent analgesic [33], probably as a
result of interaction with the opiate system. The elevation of
endogenous somatostatin-14 observed in our studymay conse-
quently contribute to a reinforcement of general anesthesia. In
addition to the changes of opiate and somatostatin peptides, we
observed the elevation of several peptides derived fromcocaine-
and amphetamine-regulated transcript protein, protachykinin-
1, SH2B adapter protein 1, gamma preprotachykinin I and
neurotensin/neuromedin N. There are no previous reports
linking these identified peptides to anesthesia.
It should be noted that in practice general anesthesia
accompanies surgical procedures, with general anesthetics
being used to reduce awareness and pain. This was also the
case in our study, where animals underwent electrode implan-
tation in the visual cortex at the beginning of the anesthesia
period. The surgery was performed in the occipital cortex, far
away from the hypothalamus where brain samples were
analyzed for peptide content. The surgery was brief, lasting
only about 45 min, occurred at the beginning of the anesthesia
period around twelve hours prior to extraction of peptides, and
also caused onlyminimal damage to the brain. In any case, our
main findings on neuropeptide changes are largely consistent
with current studies on the effects of general anesthetics
administered in the absence of surgical procedures. We
nevertheless feel that they provide an accurate picture of the
practical influence of general anesthesia that is administered
accompanying a medical or experimental surgical procedure.
Taken together, our results show that volatile anesthetics
applied during surgery can generate a broad influence on the
brain peptidergic system. We observed particularly pronounced
effects on diverse members of the opioid family, as well as on
levels of the somatostatin, preprotachykinin and neurotensin
family peptides. The involvement of peptides derived from
multiple prohormone families suggesteddifferentiatedpathways
by which volatile anesthetics impact neuropeptide expression.
5. Conclusion
We have characterized the tree shrew hypothalamic
neuropeptidome, usingpredicted-peptide database construction
and hybrid spectral analysis. Our comparative analysis revealed
that combined application of isoflurane and nitric oxide induces
remarkable changes in a considerable number of peptides. Only
some of these peptides had been previously associated with
general anesthesia, so our findings broaden the scope of the
involvement of various hypothalamic neuropeptides in general
anesthesia, providing important medical values for evaluating
the effects of general anesthesia on subjects.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jprot.2012.11.002.
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